 HIGH POINT, N.C., June 29, 2021 GLOBE NEWSWIRE -- vTv Therapeutics Inc. Nasdaq: VTVT a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis Psoriatic Arthritis Conference held virtually June 30 July 3, 2021 in Stockholm, Sweden. 